Tumor protein p53-inducible nuclear protein 1 (TP53INP1) is a tumor suppressor associated with malignant tumor metastasis. In addition, it has been reported that hsa-microRNA (miR)-3934 serves key roles in various types of lung cancer, including small-cell lung carcinomas (SCLC) and non-SCLC (NSCLC). Therefore, the present study aimed to determine the effects of miR-3934-5p on cell proliferation and apoptosis, and on sensitivity to cisplatin (DDP). Reverse transcription-quantitative polymerase chain reaction analysis and western blotting were conducted for the analysis of mRNA and protein expression, respectively. Furthermore, the target of miR-3934-5p was investigated using a luciferase reporter assay and apoptosis was analyzed by flow cytometry. The results demonstrated that miR-3934-5p was upregulated in NSCLC tissues and A549 cells. Increases in the half-maximal inhibitory concentration (IC 50 ) and the expression of miR-3934-5p were observed in the A549/DDP group. miR-3934-5p mimic promoted the expression of miR-3934-5p and the IC 50 of the A549 cells. miR-3934-5p inhibitor downregulated miR-3934-5p and reduced the IC 50 of A549/DDP cells. miR-3934-5p was revealed to target the 3′-untranslated region of TP53INP1. The downregulation of miR-3934-5p significantly suppressed the proliferation and promoted the apoptosis of A549/DDP cells, which were reversed by transfection with TP53INP1 small interfering (si)RNA. The protein and mRNA expression levels of TP53INP1, B-cell lymphoma 2 (Bcl-2)-associated-X and p21 were significantly increased, whereas those of Bcl-2 were significantly decreased in the miR-3934-5p inhibitor group, which was significantly reduced by TP53INP1 siRNA transfection. miR-3934-5p, as a tumor suppressor in NSCLC, may promote the sensitivity of cells to DDP by targeting TP53INP1, associated with the suppression of cell proliferation and promotion of apoptosis.

Purpose: To evaluate the impact of interval between chemoradiotherapy (CRT) and surgery on rates of pathological complete response (pCR). Methods: A search was carried out from PubMed and Embase databases for literature related to clinical benefits in rectal cancer patients after surgery performed at different intervals following neoadjuvant therapy. The main endpoint was the rate of pCR. Relative risk (RR) of chance of a pCR among different intervals was assessed. Results: Among 3462 screened individuals, 11 retrospective cohort studies representing 3462 relevant patients were qualified for inclusion in the study. The time intervals varied between ≤ 5 weeks and > 12 weeks. Thell studies were divided into 6 categories based on surgical timing. The potential association between the pCR rate and time intervals of 5, 6, 7, 8, 10 or 12 weeks was analyzed. Pooled RR and 95 % confidence intervals (CIs) of pCR rates at different intervals were plotted on a line chart. The highest plateau in the RR of pCR rates were noted in patients undergoing surgery beyond 7 weeks (RR, 1.60; 95 % CI,; p = 0.001) after the end of CRT. Conclusion:Radical operation over 7 weeks following CRT results in the highest risk of pCR. The question as to whether this is associated with high long-term survival rate remains to be resolved.